ArticleDiscover oncology2026
Identification of replication factor C subunit 4 as a potential therapeutic target in esophageal squamous cell carcinoma based on bioinformatic analysis and machine learning.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is one of the highly lethal and aggressive malignant tumors worldwide. To effectively prevent and treat this disease, the search for novel molecular targets is of great significance for promoting the molecular diagnosis and targeted therapy of ESCC.
methodGene expression profiles from gene expression omnibus (GEO) datasets were normalized and analyzed to identify differentially expressed genes. Functional enrichment, protein-protein interaction network, and machine learning algorithms were applied for biomarker screening. Immune infiltration analysis and immunohistochemistry were performed to assess clinical relevance.
resultsAnalysis identified 752 differentially expressed genes in ESCC, with enrichment in upregulated pathways including DNA replication and mismatch repair, and downregulated pathways such as autophagy. Gene Ontology/Kyoto Encyclopedia of Genes and Genomes analyses revealed complex molecular networks driving ESCC. Key hub genes and diagnostic biomarkers aurora kinase A (AURKA), kinesin family member 4 A (KIF4A), and replication factor C subunit 4 (RFC4) were identified, with high diagnostic area under the receiver operating characteristic curve values from 0.976 to 0.983. RFC4 expression correlated with mast cell infiltration patterns, showed elevated expression in ESCC tissues via immunohistochemistry, and was associated with poor prognosis.
conclusionThis study identifies AURKA, KIF4A, and RFC4 as potential in silico biomarkers for ESCC. This study further highlights RFC4 as a promising candidate for diagnostic and prognostic applications, offering new insights into prevention strategies for ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.